Last reviewed 2026-06-10 · How we verify

Doxorubicin Induced Cardiomyopathy — Treatment Landscape & Competitive Intelligence

Doxorubicin Induced Cardiomyopathy (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Doxorubicin Induced Cardiomyopathy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. · 1 drug in Doxorubicin Induced Cardiomyopathy
2. M.D. Anderson Cancer Center · 1 drug in Doxorubicin Induced Cardiomyopathy
3. Pfizer · 1 drug in Doxorubicin Induced Cardiomyopathy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Doxorubicin Induced Cardiomyopathy:

• Doxorubicin Induced Cardiomyopathy treatment updates — RSS
• Doxorubicin Induced Cardiomyopathy treatment updates — Atom
• Doxorubicin Induced Cardiomyopathy treatment updates — JSON

Cite this brief

Drug Landscape (2026). Doxorubicin Induced Cardiomyopathy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/doxorubicin-induced-cardiomyopathy. Accessed 2026-06-10.

Related

• Doxorubicin Induced Cardiomyopathy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing